Clinical Trials Logo

Neoadjuvant Therapy clinical trials

View clinical trials related to Neoadjuvant Therapy.

Filter by:
  • Not yet recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06404736 Not yet recruiting - Neoadjuvant Therapy Clinical Trials

QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk TNBC Breast Cancer

QUEEN-Dream
Start date: May 7, 2024
Phase: Phase 2
Study type: Interventional

This study will look at the efficacy and safety of QL1706 plus albumin-bound paclitaxel and carboplatin in a neoadjuvant setting, in high-risk, TNBC early breast cancer.

NCT ID: NCT06404463 Not yet recruiting - Neoadjuvant Therapy Clinical Trials

QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk ER+/HER2- Breast Cancer

QUEEN-Neo
Start date: May 6, 2024
Phase: Phase 2
Study type: Interventional

This study will look at the efficacy and safety of QL1706 plus albumin-bound paclitaxel followed by AC/EC in a neoadjuvant setting, in high-risk, ER+/HER2- early breast cancer.

NCT ID: NCT06356688 Not yet recruiting - Neoadjuvant Therapy Clinical Trials

A Clinical Study on the Efficacy and Safety of Paclitaxel Polymer Micelles and Cisplatin Combined With Cadonilimab as a Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma

Start date: April 20, 2024
Phase: Phase 2
Study type: Interventional

The purpose of this study is to investigate the efficacy and safety of neoadjuvant treatment of locally advanced esophageal squamous carcinoma with a PD-1/CTLA-4 bispecific antibody (cadonilimab) in combination with platinum-containing chemotherapy (paclitaxel polymer micelles combined with cisplatin). Includes pathologic complete remission rates (pCR rates) after 2-4 cycles of cadonilimab combination chemotherapy. The objective remission rate (ORR), major pathologic remission rate (MPR), R0 resection rate and 2-year overall survival (OS) and progression-free survival (OS) rates, and safety of neoadjuvant treatment of locally advanced esophageal squamous carcinoma with cadonilimab combined with chemotherapy.

NCT ID: NCT06281405 Not yet recruiting - Neoadjuvant Therapy Clinical Trials

CAPOX and PD-1 Antibody Combined With or Without Radiotherapy for MSS Locally Advanced Rectal Cancer

TORCH-iTNT
Start date: March 1, 2024
Phase: Phase 2
Study type: Interventional

TORCH-iTNT is a prospective, multicentre, randomized phase II trial. 198 LARC (T3-4/N+M0, distance from anal verge ≤12cm) patients will be treated with total neoadjuvant therapy (TNT) and assigned to Group A and Group B (1:1). Group A receives 6 cycles of Toripalimab combined with CAPOX (ToriCAPOX). Group B receives SCRT (25Gy/5Fx) followed by 6 cycles of ToriCAPOX. TME surgery is scheduled after TNT while a watch and wait (W&W) option can be applied to patients achieving clinical complete response (cCR). The primary endpoint is complete response (CR, pathological complete response [pCR] plus cCR) rate. The secondary endpoints include the grade 3-4 acute adverse effects (AE) rate, anal preservation rate, 3-year DFS rate, etc.

NCT ID: NCT06125223 Not yet recruiting - Immunotherapy Clinical Trials

PABLIXIMAB as Neoadjuvant Therapy for Head and Neck Squamous-cell Carcinoma

Start date: November 1, 2023
Phase:
Study type: Observational

The goal of this clinical trial is to learn about the efficacy and safety of pablizumab combined with neoadjuvant chemotherapy in patients with locally advanced head and neck squamous cell carcinoma. The main question it aims to answer is: Pathological complete remission (PCR) rate of tumor after neoadjuvant immunotherapy. Participants will be asked to perform CT and MRI of head and neck, ultrasonography of cervical lymph nodes and necessary laboratory examinations Before and after neoadjuvant therapy. And will be following-up for at least 1 year.

NCT ID: NCT05996484 Not yet recruiting - Neoadjuvant Therapy Clinical Trials

Neoadjuvant Therapy of Anlotinib Combined With Toripalimab and Chemotherapy for Resectable Esophageal Carcinoma

Start date: September 2023
Phase: Phase 2
Study type: Interventional

The purpose of this study is to explore the effectiveness and safety of the combination of Anlotinib, Toripalimab, and albumin-bound paclitaxel with cisplatin for neoadjuvant therapy in resectable esophageal squamous cell carcinoma. The study aims to improve the pathological complete response rate (pCR), R0 resection rate, and disease-free survival (DFS) in patients undergoing esophageal cancer surgery. The findings of this study will provide guidance and new options for the treatment of locally advanced esophageal cancer patients.

NCT ID: NCT05993858 Not yet recruiting - Clinical trials for Head and Neck Squamous Cell Carcinoma

Neoadjuvant PD-1 Inhibitor Combined With Cetuximab in Operable Locally Advanced HNSCC

PC-1
Start date: October 20, 2023
Phase: Phase 2
Study type: Interventional

This is a single-center, single-arm, phase II clinical study to evaluate the efficacy and safety of PD-1 inhibitor combined with cetuximab in neoadjuvant therapy for locally advanced HNSCC.

NCT ID: NCT05983094 Not yet recruiting - Breast Cancer Clinical Trials

Study of Utidelone Based Neoadjuvant Treatment on Early High-risk or Locally Advanced Breast Cancer

Start date: September 1, 2023
Phase: Phase 2
Study type: Interventional

The purpose of this clinical trial is to evaluate the efficacy and safety of Utidelone based regimen as neoadjuvant treatment With High-risk Early-stage or Locally Advanced Breast Cancer.

NCT ID: NCT05913570 Not yet recruiting - Colorectal Cancer Clinical Trials

Cadonilimab as Neoadjuvant Therapy in Resectable Stage II-III MSI-H/dMMR Colorectal Cancer

MSI-H/dMMR
Start date: June 20, 2023
Phase: Phase 2
Study type: Interventional

This study will evaluate the safety, and tolerability of Cadonilimab as neoadjuvant treatment for resectable local advanced colorectal cancer patient with dMMR/MSI-H.

NCT ID: NCT05833971 Not yet recruiting - Neoadjuvant Therapy Clinical Trials

Cadonilimab in Combination With Chemotherapy for Locally Advaced Esophageal Squamous Cell Carcinoma

Start date: May 1, 2023
Phase: Phase 2
Study type: Interventional

This is a single-arm, multicenter, exploratory study to evaluate the efficacy and safety of AK104 in combination with cisplatin and paclitaxel in the treatment of resectable locally advanced esophageal squamous carcinoma.